Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 12

1.

The Aryl Hydrocarbon Receptor Is Expressed in Thyroid Carcinoma and Appears to Mediate Epithelial-Mesenchymal-Transition.

Moretti S, Nucci N, Menicali E, Morelli S, Bini V, Colella R, Mandarano M, Sidoni A, Puxeddu E.

Cancers (Basel). 2020 Jan 7;12(1). pii: E145. doi: 10.3390/cancers12010145.

2.

Immune Profiling of Thyroid Carcinomas Suggests the Existence of Two Major Phenotypes: An ATC-Like and a PDTC-Like.

Giannini R, Moretti S, Ugolini C, Macerola E, Menicali E, Nucci N, Morelli S, Colella R, Mandarano M, Sidoni A, Panfili M, Basolo F, Puxeddu E.

J Clin Endocrinol Metab. 2019 Aug 1;104(8):3557-3575. doi: 10.1210/jc.2018-01167.

PMID:
30882858
3.

8th edition of the AJCC/TNM staging system of thyroid cancer: what to expect (ITCO#2).

Lamartina L, Grani G, Arvat E, Nervo A, Zatelli MC, Rossi R, Puxeddu E, Morelli S, Torlontano M, Massa M, Bellantone R, Pontecorvi A, Montesano T, Pagano L, Daniele L, Fugazzola L, Ceresini G, Bruno R, Rossetto R, Tumino S, Centanni M, Meringolo D, Castagna MG, Salvatore D, Nicolucci A, Lucisano G, Filetti S, Durante C.

Endocr Relat Cancer. 2018 Mar;25(3):L7-L11. doi: 10.1530/ERC-17-0453. Epub 2017 Nov 30. No abstract available.

4.

Are Evidence-Based Guidelines Reflected in Clinical Practice? An Analysis of Prospectively Collected Data of the Italian Thyroid Cancer Observatory.

Lamartina L, Durante C, Lucisano G, Grani G, Bellantone R, Lombardi CP, Pontecorvi A, Arvat E, Felicetti F, Zatelli MC, Rossi R, Puxeddu E, Morelli S, Torlontano M, Crocetti U, Montesano T, Giubbini R, Orlandi F, Aimaretti G, Monzani F, Attard M, Francese C, Antonelli A, Limone P, Rossetto R, Fugazzola L, Meringolo D, Bruno R, Tumino S, Ceresini G, Centanni M, Monti S, Salvatore D, Spiazzi G, Mian C, Persani L, Barbaro D, Nicolucci A, Filetti S.

Thyroid. 2017 Dec;27(12):1490-1497. doi: 10.1089/thy.2017.0299. Epub 2017 Nov 10.

PMID:
29020892
5.

Signal Transducer and Activator of Transcription 1 Plays a Pivotal Role in RET/PTC3 Oncogene-induced Expression of Indoleamine 2,3-Dioxygenase 1.

Moretti S, Menicali E, Nucci N, Voce P, Colella R, Melillo RM, Liotti F, Morelli S, Fallarino F, Macchiarulo A, Santoro M, Avenia N, Puxeddu E.

J Biol Chem. 2017 Feb 3;292(5):1785-1797. doi: 10.1074/jbc.M116.745448. Epub 2016 Dec 19.

6.

Acute liver damage following intravenous glucocorticoid treatment for Graves' ophthalmopathy.

Moleti M, Giuffrida G, Sturniolo G, Squadrito G, Campennì A, Morelli S, Puxeddu E, Sisti E, Trimarchi F, Vermiglio F, Marinò M.

Endocrine. 2016 Oct;54(1):259-268. Epub 2016 Mar 22. Review.

PMID:
27003434
7.

Timing of breakfast does not influence therapeutic efficacy of liquid levothyroxine formulation.

Morelli S, Reboldi G, Moretti S, Menicali E, Avenia N, Puxeddu E.

Endocrine. 2016 Jun;52(3):571-8. doi: 10.1007/s12020-015-0788-2. Epub 2015 Nov 4.

PMID:
26537478
8.

Autoantibody response against NALP5/MATER in primary ovarian insufficiency and in autoimmune Addison's disease.

Brozzetti A, Alimohammadi M, Morelli S, Minarelli V, Hallgren Å, Giordano R, De Bellis A, Perniola R, Kämpe O, Falorni A; Italian Addison Network.

J Clin Endocrinol Metab. 2015 May;100(5):1941-8. doi: 10.1210/jc.2014-3571. Epub 2015 Mar 3.

9.

Indoleamine 2,3-dioxygenase 1 (IDO1) is up-regulated in thyroid carcinoma and drives the development of an immunosuppressant tumor microenvironment.

Moretti S, Menicali E, Voce P, Morelli S, Cantarelli S, Sponziello M, Colella R, Fallarino F, Orabona C, Alunno A, de Biase D, Bini V, Mameli MG, Filetti S, Gerli R, Macchiarulo A, Melillo RM, Tallini G, Santoro M, Puccetti P, Avenia N, Puxeddu E.

J Clin Endocrinol Metab. 2014 May;99(5):E832-40. doi: 10.1210/jc.2013-3351. Epub 2014 Feb 11.

PMID:
24517146
10.

Therapy of adrenal insufficiency: an update.

Falorni A, Minarelli V, Morelli S.

Endocrine. 2013 Jun;43(3):514-28. doi: 10.1007/s12020-012-9835-4. Epub 2012 Nov 21. Review.

PMID:
23179775
11.

Progressive decline of residual follicle pool after clinical diagnosis of autoimmune ovarian insufficiency.

Falorni A, Brozzetti A, Aglietti MC, Esposito R, Minarelli V, Morelli S, Sbroma Tomaro E, Marzotti S.

Clin Endocrinol (Oxf). 2012 Sep;77(3):453-8. doi: 10.1111/j.1365-2265.2012.04387.x.

PMID:
22417127
12.

Autoantibody responses in autoimmune ovarian insufficiency and in Addison's disease are IgG1 dominated and suggest a predominant, but not exclusive, Th1 type of response.

Brozzetti A, Marzotti S, La Torre D, Bacosi ML, Morelli S, Bini V, Ambrosi B, Giordano R, Perniola R, De Bellis A, Betterle C, Falorni A; Italian Addison Network.

Eur J Endocrinol. 2010 Aug;163(2):309-17. doi: 10.1530/EJE-10-0257. Epub 2010 May 24.

PMID:
20498138

Supplemental Content

Loading ...
Support Center